Loading clinical trials...

THC Crossover Study | Clinical Trials | Clareo Health

COMPLETEDNA

THC Crossover Study

Cardiovascular Effects of Cannabis Compared to Tobacco Use

NCT04429568•University of California, San Francisco

Summary

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

Detailed Description

Experienced dual cannabis-tobacco smokers will participate in a within-subject crossover study with three blocks: smoked cannabis (purchased by participants from a local dispensary), dry herb cannabis vaporizer, and usual brand tobacco cigarette. Each block will consist of 2 consecutive days on an inpatient research ward. The first inpatient day of each block will comprise of two sessions: (1) The first session will be a standardized bout to compare pharmacokinetic, physiologic, and subjective effects of cannabis and tobacco use; (2) after 6 hours of abstinence, the second session will be ad libitum access to the assigned product for 2 hours to compare subjective effects (reward, satisfaction, craving reduction) and use patterns. The second inpatient day will consist of ad libitum use of the assigned product from 8:00 in the morning to midnight. An abstinence day will be added after the second day of the last block to assess exposure and effects biomarkers during a period of abstinence from cannabis (smoked/vaped) or tobacco.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy on the basis of medical history and limited physical examination, as described below:
•Heart rate \< 105 beats per minute (BPM); Systolic Blood Pressure \< 160 and \> 90\*; Diastolic Blood Pressure \< 100 and \> 50\*
•\*Considered out of range if both machine and manual readings are above/below these thresholds.
•Current regular user of cannabis who smokes cannabis as joint or blunt at least 3 times a week for past 3 months
•History of cannabis vaporizer use or willingness to use the vaporizer in the study
•Current tobacco cigarette use who smokes ≥ 5 cigarettes per day
•Saliva cotinine ≥ 50 ng/ml
•Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use

Exclusion Criteria

•Unstable medical conditions:
•Heart disease; Uncontrolled hypertension; Thyroid disease (okay if controlled with medication); Diabetes; Hepatitis B or C or Liver disease; Glaucoma; Prostatic hypertrophy
•Psychiatric conditions:
•Current or past schizophrenia, and/or current or past bipolar disorder; Adult onset attention deficit hyperactivity disorder (ADHD); Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion; History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
•Concurrent regular use of smokeless tobacco or pipes \[occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study\]
•Medications:
•Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).; Concurrent use of nicotine-containing medications; Psychiatric medications: current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.
•Other/Misc. Chronic Health Conditions:
•Oral thrush; Fainting; Untreated thyroid disease; Other "life threatening illnesses" as per study physician's discretion
•Pregnancy:
+8 more criteria

Locations (2)

Zuckerberg San Francisco General Hospital

San Francisco, California, United States

University of California, San Francisco

San Francisco, California, United States

Key Dates

Start Date

October 30, 2020

Primary Completion Date

June 25, 2024

Completion Date

June 25, 2024

Last Updated

July 1, 2024

Enrollment

ACTUAL participants

Conditions

THCCannabisCannabis SmokingCannabis Use, UnspecifiedCigarette SmokingTobacco UseNicotine DependenceNicotine WithdrawalCardiovascular Risk Factor

Interventions

Smoked Cannabis

OTHER

Vaped Cannabis

OTHER

Tobacco Cigarette

OTHER

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGNA

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

NCT06878859

Depression - Major Depressive DisorderCannabis Use Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

THC Crossover Study

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Integrating Systems and Basic Income: Improving Outcomes for Families of Young Children

Ethnic Minorities Experiences of Healthcare Intervention

In-Vehicle Real-Time Cannabis Influenced Driving Detection

Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use